Maze Therapeutics (NASDAQ:MAZE) Raised to Strong-Buy at Leerink Partnrs

Maze Therapeutics (NASDAQ:MAZE) was upgraded by Leerink Partnrs to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

Other analysts have also recently issued reports about the stock. Guggenheim initiated coverage on shares of Maze Therapeutics in a research note on Tuesday. They set a “buy” rating and a $19.00 price objective for the company. Leerink Partners initiated coverage on shares of Maze Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $28.00 price objective for the company. Finally, JPMorgan Chase & Co. started coverage on shares of Maze Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $30.00 price objective for the company.

Maze Therapeutics Trading Down 2.3 %

Shares of NASDAQ MAZE opened at $10.57 on Tuesday. Maze Therapeutics has a 52-week low of $10.08 and a 52-week high of $17.00.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.